ESMO Congress – 2021

By 8 septembre 2021Actualités, News

NETRIS Pharma is pleased to announce that a “trial in progress” abstract has been accepted to the ESMO congress (European Society for Medical Oncology) taking place September 16th-20th.

The corresponding e-Poster “GYNET – Safety & efficacy of NP137 in combination with chemotherapy and/or Pembrolizumab in patients with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: an adaptative multi-arms randomized Phase I/II” was presented by Prof. Isabelle Ray-Coquard as Principal Investigator.